NCT03030378 2026-03-19
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
39 trialsNCT04958239 2026-03-17
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07474168 2026-03-16
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Phase 1 Active not recruiting
NCT05707910 2026-03-09
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT04294628 2026-02-27
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting
NCT04170153 2026-01-30
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Phase 1 Active not recruiting
NCT03065387 2026-01-12
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02560636 2026-01-06
PLUMMB
Royal Marsden NHS Foundation Trust
Phase 1 Active not recruiting
NCT04898543 2025-12-11
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Active not recruiting
NCT05631899 2025-11-24
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT04520711 2025-11-19
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
Phase 1 Active not recruiting
NCT00463814 2025-11-13
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
AstraZeneca
Phase 1 Active not recruiting
NCT01187199 2025-10-27
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04446351 2025-10-27
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT04197713 2025-10-20
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06188208 2025-10-16
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
Phase 1 Active not recruiting
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01061515 2025-09-17
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT02099058 2025-08-14
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT06547957 2025-08-13
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Active not recruiting
NCT06980454 2025-07-08
Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
Shanghai Henlius Biotech
Phase 1 Active not recruiting
NCT04648202 2025-06-27
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
invoX Pharma Limited
Phase 1 Active not recruiting
NCT05714748 2025-06-04
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT05678010 2025-05-18
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04419532 2025-04-09
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Active not recruiting
NCT04401020 2025-03-21
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Sanofi
Phase 1 Active not recruiting
NCT04627246 2025-02-25
Personalized Vaccine with SOC Chemo Followed by Nivo in Pancreatic Cancer
Centre Hospitalier Universitaire Vaudois
Phase 1 Active not recruiting
NCT05349890 2024-11-25
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
Phase 1 Active not recruiting
NCT03568058 2024-11-13
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Phase 1 Active not recruiting
NCT04130542 2024-10-31
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Active not recruiting
NCT04635995 2024-10-31
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Active not recruiting
NCT05548634 2024-10-23
TAVO412
Tavotek Biotherapeutics
Phase 1 Active not recruiting
NCT05076552 2024-08-01
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Tachyon Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05300438 2024-06-25
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
Tyligand Bioscience (Shanghai) Limited
Phase 1 Active not recruiting
NCT02193503 2023-09-28
MVX-ONCO-1 in Patients With Solid Tumor
Maxivax SA
Phase 1 Active not recruiting